Compare Simon Property Group Inc (SPG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Simon Property Group Inc trades at $200.57 (market cap $64.92B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Simon Property Group Inc is far larger — about 13.3× Travere Therapeutics Inc. Common Stock's market cap, and Simon Property Group Inc pays a 4.44% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Simon Property Group Inc for 100 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SPG | TVTX | |
|---|---|---|
Market Cap | $64.92B | $4.88B |
Volume | 1,919,136 | 1,668,577 |
Sector | Real Estate | Health |
52-Week High | $236.70 | $67.52 |
52-Week Low | $173.35 | $26.79 |
Typical Hold Time | 100 Days | 0 Days |
Enterprise Value | $93.37B | $5.01B |
Dividend Yield | 4.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $198.70, down 1.35% with bearish technical signals from moving averages and ADX indicators. The REIT maintains strong fundamentals with Q4 2025 EPS beating expectations at $9.35 versus $1.90, though Q2 2026 missed at $1.49 versus $1.64. Recent news highlights strong leasing demand and a new $800 million debt issuance, while directors made small stock purchases in late September 2026.
SPG presents a mixed outlook with robust profitability metrics like 66.57% net margin and 135.7% ROE offset by negative net cash flow and high debt levels. The consensus price target of $218.45 suggests 10% upside potential, but rising bond yields and $2B in 2024 debt maturities pose headwinds for the retail REIT sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
